Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 9/20 | 0.41 |
| ▸ | CA2 | P00918 | 9/20 | 0.41 |
| ▸ | CA12 | O43570 | 8/20 | 0.41 |
| ▸ | CA4 | P22748 | 7/20 | 0.41 |
| ▸ | CA5A | P35218 | 7/20 | 0.41 |
| ▸ | CA7 | P43166 | 7/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 7/20 | 0.41 |
| ▸ | MAOB | P27338 | 5/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3941757 | 0.95 | CA1 (0.40) | SLC2A1KCNH2CA1CA2CA12 | |
| SCHEMBL3940954 | 0.93 | SLC2A1 (0.43) | SLC2A1KCNH2CA1CA2CA12 | |
| SCHEMBL3938422 | 0.92 | CA1 (0.45) | KCNH2CA1CA2CA12CA4 | |
| SCHEMBL3936856 | 0.92 | CA1 (0.41) | SLC2A1KCNH2CA1CA2CA12 | |
| SCHEMBL3936271 | 0.92 | SLC2A1 (0.42) | SLC2A1KCNH2CA1CA2CA12 | |
| SCHEMBL3945972 | 0.91 | SLC2A1 (0.40) | SLC2A1KCNH2SLC22A12CYP3A4MAPT | |
| SCHEMBL3946314 | 0.89 | SLC2A1 (0.42) | SLC2A1KCNH2CA1CA2CA12 | |
| SCHEMBL3937859 | 0.89 | CA1 (0.43) | SLC2A1CA1CA2CA12CA4 | |
| SCHEMBL3936840 | 0.89 | CA1 (0.40) | SLC2A1KCNH2CA1CA2CA12 | |
| SCHEMBL3942957 | 0.89 | KCNH2 (0.45) | SLC2A1KCNH2CYP3A4MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046731-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-04-15 | — | — | EP | claimed |
| WO-2008009613-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-24 | — | — | WO | claimed |
| US-20080020981-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2008-01-24 | — | — | US | claimed |
| EP-2046731-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008009613-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-24 | — | — | WO | disclosed |
| US-20080020981-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080020981-A1 | Non-nucleoside reverse transcriptase inhibitors | SAMHD1, HPRT1, NQO2 | SLC2A1 2799/4885KCNH2 4114/4885CA1 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.